Vision

PRECEDE AND TROVANOW ARE DEDICATED TO INCREASING THE SURVIVAL RATE FOR PANCREATIC CANCER THROUGH A UNIQUE COLLABORATIVE MODEL OF DATA SHARING AMONG THE TOP MEDICAL AND EXPERTS ON PANCREATIC CANCER THROUGHOUT THE WORLD. BY SHARING OUR DATA AND BIOSAMPLES WE HAVE ESTABLISHED A UNIQUE STUDY WITH THE POWER NEEDED TO DEVELOP AND VALIDATE EFFECTIVE EARLY DETECTION TOOLS

Goals

1. 1.WE HAVE SUCCESSFULLY BROUGHT TOGETHER OVER 60 ACADEMIC MEDICAL CENTERS AND THEIR SCIENTIST AND CLINICIANS WHO HAVE ALL AGREED TO SHARE DATA, RESEARCH AND BIOSAMPLES TO ADDRESS THE DEADLIEST CANCER OF OUR TIME WITH ONLY A 13% SURVIVAL RATE. WE CURRENTLY HAVE SITES IN THE US, CANADA, ITALY, SPAIN, ISRAEL, HUNGARY, ENGLAND. AUSTRALIA, ICELAND, AND JAPAN. WE ARE CONTINUING TO GROW OUR COLLABORATION.
2. 2.OVER THE LAST 4 YEARS, WE HAVE BEEN ABLE TO ENROLL OVER 8300 INDIVIDUALS AT HIGH RISK FOR DEVELOPING PANCREATIC CANCER INTO OUR SCREENING AND SURVEILLANCE PROGRAM. WE ARE COMMITTED TO REACHING AT LEAST 10,000 PARTICIPANTS IN THE NEXT 2-3 YEARS. AN IMPORTANT GOAL OF THE CONSORTIUM IS TO ENSURE THAT OUR PARTICIPANTS ARE REPRESENTATIVE OF ALL COMMUNITIES AT RISK INCLUDING MINORITY POPULATIONS.
3. 3.OUR GOAL IS TO PARTNER WITH COMPANIES WITH POTENTIAL BIOMARKERS FOR PANCREATIC CANCER. IF SUCCESSFUL, THE BIOMARKERS WILL ENABLE INDIVIDUALS AT RISK TO HAVE THEIR CANCER DETECTED AT ITS EARLIEST STAGE. PATIENTS DIAGNOSED IN STAGE 0 OR 1 HAVE BETWEEN A 98% AND 69% SURVIVAL RATE. BY THE TIME YOU GET TO A STAGE IV DIAGNOSIS IT DROPS TO 1%. 79% OF PEOPLE ARE CURRENTLY DIAGNOSED AT STAGE 3 OR 4.